Radical Numerics
Category: AI in Biotech / Drug Discovery
AI research lab building general biological intelligence: multimodal genome language models (Omnii) that read, write and interpret biology, with a dual mandate of drug discovery and biodefense. Radical Numerics was founded in 2025. The company is led by Eric Nguyen. Based in San Francisco, United States. Team size: 11-50. Total funding raised: $50M. Latest round: Seed. Key investors include Emergence Capital (lead), Obvious Ventures, Triatomic Capital, Factory, First Spark Ventures, Patrick Collison (pre-seed).
- Founded
- 2025
- Headquarters
- San Francisco, United States
- Team size
- 11-50
- Total funding
- $50M
Value proposition
One multimodal model (Omnii-1) that learns across 28 types of biological data (DNA, RNA, proteins, epigenetic signals) to predict biological effects, generate sequences with desired functions and detect biological threats beyond known sequence matches.
Products and solutions
Omnii-1 multimodal genome language model, Omnii Diagnostics (cancer detection from blood), Omnii Cancer Vaccine, Omnii Genetics (rare disease), Omnii Defense (offline edge pathogen-flagging model, limited to vetted testers), Omnii Genome, Omnii Antibody, Omnii Phage (first AI-designed phage therapy given to a patient), Omnii Rare Earth (proteins for rare earth separation)
Unique value
Whole-system, multimodal learning across biological signals in a single model, rather than single-modality tools; Omnii Defense predicts function and AI-generation likelihood instead of relying only on sequence matches, and runs offline on a laptop with a USB gene sequencer.
Target customer
Pharma and biotech partners, diagnostics developers, national laboratories, government and biodefense agencies, and public health researchers
Industries served
Biotech / drug discovery, diagnostics (cancer), biodefense / biosecurity, rare disease genetics, critical minerals
Technology advantage
Founders created the Hyena long-context architectures and the Evo / Evo 2 generative genomics models; multimodal genome language model architecture; edge deployment. Future model releases will not automatically be open-source.
How they differentiate
Multimodal, genome-anchored model covering many biological signals in one model, versus single-modality competitors (proteins, RNA); dual mandate pairing therapeutics with biodefense.
Main competitors
EvolutionaryScale, Inceptive, Isomorphic Labs
Key partnerships
Unnamed national laboratory (pathogen detection and characterization), unnamed pancreatic and multi-cancer detection partner, Tabula Bioscience (former partner on the Omnii phage work, now disputed), working with government agencies and independent evaluators to assess Omnii Defense. Advisors include Tri Dao, Eric Horvitz, Chris Ré, Jill Hruby, Andrew Weber and Paul Friedrichs. George Church resigned as advisor in November 2026.
Major milestones
2025: founded by the Evo / Evo 2 research team. 2026-06: emerged from stealth with $50M seed. 2026-10: launched Omnii-1 and reported the first AI-designed phage therapy given to a human patient (FDA special permission), credit dispute with Tabula Bioscience followed. 2026-11: announced Omnii Defense, George Church resigned as advisor.
Market positioning
Frontier AI-for-biology research lab positioned as a well-capitalised early-stage player in generative genomics and biosecurity.
Geographic focus
United States / global
About Eric Nguyen
Ex-Google DeepMind Co-Scientist team and Google Research; PhD Bioengineering & AI, Stanford (started the Evo project); MEng, Cornell. Co-creator of Evo and Evo 2 genome language models.
Latest news about Radical Numerics
More AI in Biotech / Drug Discovery companies
Official website: https://www.radicalnumerics.ai